Effects of etomidate and propofol on immune function in patients with lung adenocarcinoma

Jiapeng Liu, Wei Dong, Tao Wang, Liang Liu, Long Zhan, Yifei Shi, Jiange Han

Department of Anesthesiology, Tianjin Chest Hospital, Tianjin 300222, P R China

Received April 1, 2016; Accepted April 22, 2016; Epub December 15, 2016; Published December 30, 2016

Abstract: Objective: To investigate the effects of etomidate and propofol on immune function in patients with lung adenocarcinoma. Methods: Sixty patients who were scheduled for lung cancer surgery under general anesthesia were studied. The patients were randomly divided into an etomidate total intravenous anesthesia group (group E) and a propofol total intravenous anesthesia group (group P), with 30 cases in each group. Results: Within group comparison: The percentage of CD4+ in the two groups was significantly reduced at 24 hours post-operation (T₂) compared with the percentage before surgery, whereas the percentage of CD8+ was higher at T₁. Between group comparison: The CD4+ percentage of group E was higher than that of group P (P < 0.05) at T₂, whereas the CD8+ percentage was lower than that of group P (P < 0.05) at T₁. Conclusion: Using etomidate for anesthesia has less of an effect on immune function in patients with lung adenocarcinoma.

Keywords: Etomidate, propofol, immune function, general anesthesia, lung adenocarcinoma
stímulos by blocking central conduction; and (5) as confirmed in animal experiments, nerve block can be controlled by the degree of stress to avoid excessive stress-induced immune suppression, thereby reducing the immune suppression caused by postoperative infection, delayed recovery and tumor metastasis [7]. Therefore, epidural anesthesia combined with general anesthesia may improve cancer patient outcomes.

Cata [4] has observed natural killer (NK) cell and T cell subsets in patients with non-small cell lung cancer, and found that in preoperative samples compared with preoperative samples, the number of functional T cell and NK cell subsets, as well as the CD4+/CD8+ levels, significantly decreased. However, Cata observed no significant differences in TH1/TH2 ratios. The study has shown that patient immune function decreases after surgery, whereas epidural anesthesia combined with general anesthesia has no protective effect on immune function. However, various researchers have observed that epidural anesthesia combined with general anesthesia affects survival time in gynecologic stages IIIIC and IV ovarian cancer patients with tumor recurrence. Their studies have shown that epidural anesthesia combined with general anesthesia, compared with the simple application of complete anesthesia, does not result in statistically significant differences in patients’ tumor recurrence and survival time [5].

In contrast to the two views described above, the 1999-2008 program, in which different anesthesia regimens were delivered to small cell liver cancer patients undergoing radiofrequency ablation, has indicated that the rate of tumor recurrence in anesthesia patients receiving an epidural is lower than it is in patients receiving anesthesia. However, significant differences in survival time were not found for the different anesthesia methods. Therefore, the study results suggest that local anesthesia may be beneficial for tumor prognosis in certain types of tumors [6].

Conclusions from previous studies are not consistent, thus suggesting that the effects of anesthesia methods on cancer patient outcomes are complex, and many factors are involved. As a result, it is difficult to reach consistent conclusions, but it is clear that different anesthesia methods affect tumor outcomes.

The majority of studies have suggested that narcotic drugs, including intravenous anesthetics, inhalation anesthetics and analgesics, affect tumor growth and metastasis. Among intravenous anesthetics, propofol is the most commonly used in clinical anesthesia. In recent years, researchers have published considerable information regarding propofol and tumor surgery patient outcomes. With respect to inhalation anesthetics, the protective effects of propofol on immune function are more significant, and propofol exhibits a good inhibitory effect on tumor recurrence and metastasis. Studies have shown that propofol inhibits vascular proliferation and regeneration of esophageal squamous cell carcinoma and metastasis lesions by reducing ERK-VEGF/MMP-9 signaling [8]. In addition, a study of propofol in patients with hepatocellular carcinoma has found that propofol significantly increases the expression of miR-199a and down-regulates the expression of MMP-9. In addition, miR-199a up-regulates the expression of MMP-9 and also has a feedback inhibitory effect on MMP-9 expression; thus, reduced MMP-9 expression may play a role in suppressing cancer cell invasion [9]. Propofol also synergizes with chemotherapeutic drugs in inducing apoptosis in cancer cells [10]. Studies have shown that propofol inhibits ovarian tumor cell proliferation while enhancing the role of paclitaxel-induced apoptosis in cancer cells.

Most previous studies have suggested that inhalation anesthetics inhibit NK cell activity, which is conducive to tumor growth and metastasis. Isoflurane and halothane have been found to inhibit NK cell activity in animal studies, and sevoflurane causes the release of cytokines (IL-1 and TNF) and may also have additional effects [11]. Animal studies have suggested that nitrous oxide may promote the growth of liver, lung and colon cancer. However, no significant correlation of this treatment with the prognosis of cancer patients has been found [12]. Some researchers have also compared the effects of inhalation anesthesia and intravenous anesthesia on immune function in patients with oral malignancy. One study has found that immune suppression is not as potent in patients receiving intravenous anesthesia; thus, the intravenous anesthetic drug-related effects on the suppression of immune activity may be stronger for inhaled anesthetics [13].
In contrast with propofol, opioids promote tumor cell proliferation, differentiation, metastasis and angiogenesis. This effect may be related to opioid receptor regulation; therefore, some researchers have hypothesized that opioid receptor antagonists might have anti-tumor effects [14]. In addition, Dylan has indicated that the increased use of opioids is associated with shortened survival in prostate cancer patients. However, the effects of opioids on cancer patient outcomes must be further confirmed in prospective randomized studies [15].

However, some researchers have put forward different views. One study has found that opioid receptor activation suppresses tumor proliferation and differentiation in breast cancer patients [16]. Yamamizu has suggested that κ receptor activation via inhibition of VEGF signal expression inhibits tumor tissue angiogenesis [17].

In addition, the widely used non-barbiturate intravenous anesthetic etomidate has a rapid onset, short duration of action and minimal effects on hemodynamics characteristics, particularly for the induction of anesthesia in critically ill patients. Thus, etomidate has been increasingly used to maintain anesthesia for minor surgeries [18]. However, for traumatic surgeries, including thoracotomy, the use of etomidate for the maintenance of anesthesia is uncharacterized. Here, we sought to compare the effects of etomidate and propofol in the maintenance of anesthesia on T lymphocyte subsets in lung adenocarcinoma patients to explore the effects of different maintenance anesthesia medications on patients’ immune function.

Materials and methods

Case selection

This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Tianjin Chest Hospital, Tianjin, China. In total, 60 patients scheduled for elective lung adenocarcinoma surgery under general anesthesia with good cardiac and lung function were studied. The patients were graded as ASA I-II. The patients were 48 to 67 years old (33 male cases, 27 female cases). All of the patients agreed on the methods of anesthesia. Patients with a history of immune system diseases were excluded. Patients undergoing radiotherapy and chemotherapy, taking immunosuppressive agents or undergoing perioperative blood transfusions were also excluded. The exclusion criteria included a history of immune system diseases; radiotherapy; chemotherapy; corticosteroids and other immunosuppressive drug therapies; and preoperative, intraoperative and postoperative (within 3 days) allogeneic blood transfusions.

Block methods

Sixty patients were divided into two groups by using a random sampling method: the propofol target controlled infusion group (P group) and the continuous infusion of etomidate group (E group). General anesthesia combined with thoracic epidural anesthesia was administered to both groups. However, one group (group P) was subjected to target-controlled infusion with propofol, whereas the other group (group E) was subjected to etomidate continuous infusion. The two groups of patients were treated with general anesthesia combined with thoracic epidural anesthesia.

Anesthetic management

Prior to anesthesia (0.5 hours), the patients were administered 0.01 mg/kg of intramuscular midazolam and 0.1 mg/kg of morphine. After each patient entered the operating room, routine monitoring of ECG (II, V leads), pulse oximetry and bispectral index (BIS) (VISTA, USA) were performed. In addition, row radial artery catheterization was used to monitor arterial blood pressure. When each patient was in a lateral position, the thoracic epidural catheterization puncture point T4-5 was selected, and T3-8 were maintained under anesthesia as well. Anesthesia was induced with intravenous rapid induction drugs: 0.1 mg/kg of midazolam, 3 mg/kg of etomidate (production batch number: 20141202, Jiangsu En Hua Pharmaceutical Co., Ltd.), 0.6 mg/kg of rocuronium and 1 μg/kg of sufentanil. For tracheal intubation, a bronchoscope was orally inserted under direct vision for double-lumen endotracheal intubation and mechanical ventilation with a tidal volume of 8-10 ml/kg and a respiratory rate of 10 to 12 times/min. Maintenance of anesthesia: Group P was administered propofol via target
Effect of etomidate and propofol on immune function

Table 1. General patient data

<table>
<thead>
<tr>
<th>Group</th>
<th>Age</th>
<th>Body weight (kg)</th>
<th>Gender (Male/Female)</th>
<th>ASA Grade (I/II)</th>
<th>Operation time (min)</th>
<th>Amount of bleeding (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>55 ± 5</td>
<td>59.7 ± 9.8</td>
<td>17/13</td>
<td>14/16</td>
<td>171.8 ± 15.3</td>
<td>191.5 ± 28.3</td>
</tr>
<tr>
<td>E</td>
<td>58 ± 5</td>
<td>61.2 ± 7.2</td>
<td>16/14</td>
<td>15/15</td>
<td>163.5 ± 17.5</td>
<td>205.4 ± 20.7</td>
</tr>
</tbody>
</table>

Figure 1. Information from group P and group E patients at each time point. HR, MAP and SpO2 comparisons are reported as the mean ± standard deviation. At the same time points, no significant differences in HR, MAP or SpO2 were observed.

controlled infusion with a 1-3 μg/ml target plasma propofol concentration. Group E received a continuous infusion of etomidate, and the rate of infusion was 10-20 μg/kg/min. Two patients using a muscle relaxant were intermittently administered 0.2 mg/kg of cisatracurium. The epidural analgesia was administered intermittently using 0.375% ropivacaine (5 ml, AstraZeneca). A BIS value of 40 to 60 was maintained during surgery in both groups. Spontaneous breathing, strong coughing, strong swallowing and regaining consciousness occurred at the end of the surgery. The blood gas analysis was normal, and no airway obstruction was observed. The tidal volume was consistently greater than 8 ml/kg extubation after the administration of continuous epidural analgesia.

Samples collected and indicator tests

Five milliliters of blood was collected from the patients before anesthesia (T₀), immediately after the operation (T₁) and at 24 (T₂) and 72 (T₃) hours post-operation. Flow cytometry was used to assess the CD4+ and CD8+ percentages and the CD4+/CD8+ levels. The mean arterial pressure (MAP) was also recorded at each time point. In addition, heart rate (HR), BIS, the recording time, awake extubation time, intraoperative and postoperative twitching, injection pain, nausea, vomiting and other adverse reactions were also recorded.

Statistical analysis

The data were analyzed using the statistical software package SPSS 17.0 and summarized as means ± standard errors. A one-way ANOVA was used between groups, and a repetitive measure analysis of variance was used within groups at the 5% level.

Results

General patient data

In this study, the propofol group (P) and the etomidate infusion group (E) each included 30 patients. The age (55 ± 5 vs 58 ± 5), body weight (59.7 ± 9.8 vs 61.2 ± 7.2), gender (17/13 vs 16/14), ASA classification (14/16 vs 15/15) and other aspects of the two groups were not significantly different. The operation times of the two groups were approximately 3 h (171.8 ± 15.3 vs 163.5 ± 17.5), and the amount of bleeding during surgery (191.5 ± 28.3 vs 205.4 ± 20.7) was not significantly different, as noted in Table 1.

Mean arterial pressure

The MAP, HR and pulse oxygen saturation (SpO₂) were compared at each time point. The MAP, HR and SpO₂ values did not significantly
Effect of etomidate and propofol on immune function

Table 2. The two groups of patients after surgery and the occurrence of adverse reactions

<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>Muscle trembling (%)</th>
<th>Nausea (%)</th>
<th>Vomiting (%)</th>
<th>Injection pain (%)</th>
<th>Thrombophlebitis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>30</td>
<td>0 (0.0%)</td>
<td>4 (13.3%)</td>
<td>3 (10.0%)</td>
<td>5 (16.7%)</td>
<td>2 (6.7%)</td>
</tr>
<tr>
<td>E</td>
<td>30</td>
<td>2 (6.7%)</td>
<td>5 (16.7%)</td>
<td>3 (10.0%)</td>
<td>2 (6.7%)</td>
<td>1 (3.3%)</td>
</tr>
</tbody>
</table>

Numbers with different letters (a, b) are significantly different.

Differ between the groups (P > 0.05), as shown in Figure 1.

Adverse events [cases (%)]

As shown in Table 2, group P did not exhibit the twitching phenomenon induced by anesthesia, but two patients in group E twitched (0 vs 6.7%). Nausea occurred in 4 and 5 cases (13.3 vs 16.7%) in groups P and E, respectively. Three cases of vomiting were noted in both groups (10 vs 10%). More patients reported injection in group P than in group E (16.7 vs 6.7%, P < 0.05), and the incidence of thrombophlebitis was higher in group P than in group E (6.7 vs 3.3%, P < 0.05).

Patients with CD4+ (%), CD8+ (%) and CD4+/CD8+

Within group comparisons: CD4+ significantly decreased at 24 h post operation (T2) (34.46 ± 3.93 vs 26.01 ± 8.06, P < 0.05), and CD8+ at T2 increased (29.01 ± 5.82 vs 36.57 ± 8.52; 25.24 ± 3.97 vs 35.89 ± 7.38, P < 0.05), compared with preoperative (T0) values. No significant differences in T1 and T3 were noted compared with T0. Between groups comparison: After 24 h (T2), the CD4+ percentage was higher in group E than in group P (26.01 ± 8.06 vs 38.21 ± 13.09, P < 0.05, respectively). In the immediate postoperative (T1) period, the CD8+ percentage was lower in group E than in group P (27.26 ± 1.71 vs 22.65 ± 3.61, P < 0.05, respectively). The remaining values were not significantly different between the two groups, as shown in Figure 2.

Discussion

Etomidate is a non-barbiturate intravenous anesthetic that adjusts γ-aminobutyric acid A (GABA) receptors to produce anesthesia [19]. The drug exhibits a rapid onset short duration and has a mild effect on hemodynamic features. Based on recent etomidate research, an increasing number of researchers believe that etomidate’s inhibition of adrenal cortex function is transient in nature and can be maintained in secure applications in anesthesia [20].

In this study, an etomidate infusion rate of 10-20 µg/kg/min was maintained within the desired range of BIS values for most surgical patients, and the effect of the propofol target concentration of 1-3 µg/ml was readily achievable [21]. No differences in MAP, HR and SpO2 were noted in the etomidate and propofol groups. Although secondary to epidural analge-
Effect of etomidate and propofol on immune function

Twitching is the most common complication of etomidate-induced anesthesia, and this complication may prevent the use of sedatives, analgesics and muscle relaxants [23]. In this study, the induction of anesthesia with composite applications of midazolam and sufentanil promoted stable sleep in patients. After the first application of rocuronium and before the application of etomidate, the muscle tremor incidence was 6.7%, which is significantly lower than the previously reported incidence [24].

In this study, the incidence of injection pain (6.7%) was significantly reduced in the etomidate group compared with the propofol group (16.7%). Thus, other composite applications, such as midazolam and sufentanil, may be used. Specifically, etomidate ester solvent emulsions contain 20% long-chain triglycerides, close to physiological osmolality. The propofol solvent is a long-chain triglyceride and is likely to be the cause of patient pain on injection. Compared with propofol, etomidate exhibits almost no vascular stimulation. Additional composite applications include sedative and analgesic drugs. Reductions in the injection rate and proper injection site selection are also important for the relief of pain upon injection [25].

This observation suggests that etomidate for lung resection can allow the maintenance of general anesthesia, to further maintain hemodynamic stability, an adequate depth of sedation and a low incidence of adverse reactions of the target. Weng and others have reported that etomidate maintains anesthesia with stable hemodynamics, rapid waking and a low incidence of adverse event characteristics, and that it can be safely used in the maintenance of anesthesia [26].

The body's immune response to cancer is very complex and mainly involves cellular immunity, humoral immunity and cytokines. Cellular immunity is an important part of the immune system. CD4+ and CD8+ cells are important T lymphocyte effector cells: CD4+ cells help B cells differentiate to produce antibodies and activate other cellular immune responses, and CD8+ cells suppress the immune function and inhibit antibody secretion, synthesis and proliferation. Changes in the CD4+/CD8+ ratio indicate immune function disorder. T lymphocyte subsets may serve as an indicator of immune function in lung adenocarcinoma patients [27].

Surgical trauma and anesthesia drugs can affect immune function in patients with lung cancer [28]. The perioperative selection of the correct method of anesthesia and anesthetic drugs may protect patients' immune function, treatment and prognosis; thus, cancer patients should play an active role in the choice of anesthesia. Some studies have shown [29] that propofol inhibits vascular proliferation and regeneration of esophageal squamous cell carcinoma and metastasis lesions through reduced ERK-VEGF/MMP-9 signaling. Several studies have shown [30-31] that the protective effect of propofol on immune function is significant and that propofol exhibits an inhibitory effect on tumor recurrence and metastasis. As an anesthetic maintenance medication, the effect of etomidate on immune function was assessed. Levels of CD4+ cells were significantly lower 24 h after surgery than before surgery, whereas levels of CD8+ cells were significantly higher after surgery than before surgery. These results suggest that after lung cancer patients undergo a surgical procedure, their immunity further declines. At 72 h, CD4+ and CD8+ cells gradually returned to preoperative levels, suggesting that the patient's immune function gradually recovered. Compared with propofol, a higher percentage of CD4+ cells were observed in group P than in the etomidate group 24 h after intravenous maintenance, thus suggesting that etomidate has a minimal effect on CD4+ cells. In addition, immune function recovered more rapidly after surgery in these patients. At the remaining time points, no significant differences in the effects of etomidate on the T cell subsets were observed, and the effect of etomidate on immune function in patients was similar to that of propofol. This study shows that the use of anesthesia for surgery and anesthesia medication affects immune function via a transient suppression that is quickly restored. For maintaining anesthesia, the use of etomidate has no significant inhibitory effect on immune function in patients.
Ji’s studies [32-33] have shown that etomidate exhibits minimal inhibition of circulatory function and that it is a good drug to maintain intravenous anesthesia. However, these studies did not observe its effects on immune function. Our research suggests that etomidate is ideal for lung cancer patients because it offers hemodynamic stability during the maintenance of anesthesia, and no significant adverse reactions were observed perioperatively. Regarding immune function maintenance, etomidate maintains patient CD4+ and CD8+ cell levels. Similarly, propofol has no inhibitory effect on the CD4+/CD8+ ratio.

Acknowledgements

This project was financially supported by the Tianjin Medical Association of Anesthesiology Young Researchers Nurture Fund Project (TJMZJJ-2014-01) of China.

Address correspondence to: Jiange Han. Department of Anesthesiology, Tianjin Chest Hospital, No. 261, Taierzhuang South Road, Jinnan District, Tianjin 300030, P R China. Tel: +86-22-88185152, +86-13821001156; E-mail: hanjiange@163.com

References


Effect of etomidate and propofol on immune function


